Literature DB >> 22221745

Patient time costs and out-of-pocket costs in hepatitis C.

Carole A Federico1, Priscilla C Hsu, Mel Krajden, Eric M Yoshida, Karen E Bremner, Alan A Weiss, Frank H Anderson, Murray D Krahn.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) infection is associated with substantial costs to patients, their caregivers and society. AIMS: We evaluated time costs (time spent seeking healthcare) and out-of-pocket (OOP) costs for patients with HCV and their caregivers.
METHODS: We measured costs for 738 HCV outpatients in a tertiary-care clinic using a patient-completed questionnaire. Time and OOP costs were compared across disease stages and sociodemographic categories. We examined the association between cost and disease stage using linear regression adjusting for age, gender, marital status, education, income and Index of Coexistent Disease (ICED) comorbidity score. Costs were expressed in 2007 Canadian dollars.
RESULTS: The mean annual time cost per patient was $2136 (98 h), and ranged from $281 (18 h) in individuals who had cleared the virus to $9416 in transplant recipients (420 h). Caregiver costs were reported in 10% of patients. The mean annual OOP cost per patient was $1326. Patients receiving active treatment and those with late-stage disease spent $2500-2800 per year on HCV-related healthcare, approximately 7% of their annual income. Patients who had cleared the virus had the lowest time and OOP costs. Low income and unemployed patients had higher costs.
CONCLUSIONS: In HCV-infected individuals, OOP and time costs represent a significant economic burden and fall disproportionately upon those least able to afford them. The lower cost burden among those who were successfully treated suggests that wider use of antiviral therapy may reduce economic burden in addition to improving health outcomes.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22221745     DOI: 10.1111/j.1478-3231.2011.02722.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  9 in total

1.  Opportunity costs of ambulatory medical care in the United States.

Authors:  Kristin N Ray; Amalavoyal V Chari; John Engberg; Marnie Bertolet; Ateev Mehrotra
Journal:  Am J Manag Care       Date:  2015-08       Impact factor: 2.229

2.  Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.

Authors:  Donna M Evon; Carol E Golin; Paul Stewart; Michael W Fried; Shani Alston; Bryce Reeve; Anna S Lok; Richard K Sterling; Joseph K Lim; Nancy Reau; Souvik Sarkar; David R Nelson; K R Reddy; Adrian M Di Bisceglie
Journal:  Contemp Clin Trials       Date:  2017-03-22       Impact factor: 2.226

Review 3.  Hepatitis C models of care: approaches to elimination.

Authors:  Mia J Biondi; Jordan J Feld
Journal:  Can Liver J       Date:  2020-06-04

4.  Gaps in the hepatitis C continuum of care among sex workers in Vancouver, British Columbia: Implications for voluntary hepatitis C virus testing, treatment and care.

Authors:  M Eugenia Socías; Kate Shannon; Julio S Montaner; Silvia Guillemi; Sabina Dobrer; Paul Nguyen; Shira Goldenberg; Kathleen Deering
Journal:  Can J Gastroenterol Hepatol       Date:  2015-10-22

5.  Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada.

Authors:  Claire de Oliveira; Karen E Bremner; Andy Ni; Shabbir M H Alibhai; Audrey Laporte; Murray D Krahn
Journal:  J Cancer Surviv       Date:  2013-08-23       Impact factor: 4.442

6.  The societal burden of chronic liver diseases: results from the COME study.

Authors:  Luciana Scalone; Stefano Fagiuoli; Roberta Ciampichini; Ivan Gardini; Raffaele Bruno; Luisa Pasulo; Maria Grazia Lucà; Francesco Fusco; Laura Gaeta; Anna Del Prete; Giancarlo Cesana; Lorenzo Giovanni Mantovani
Journal:  BMJ Open Gastroenterol       Date:  2015-03-30

7.  A Randomized Controlled Trial to Assess the  Impact of Clinical Pharmacy Interventions on Treatment Outcomes, Health Related Quality of Life and Medication Adherence Among Hepatitis C Patients.

Authors:  Salamat Ali; Mashhood Ali; Vibhu Paudyal; Faisal Rasheed; Shahan Ullah; Sayeed Haque; Tofeeq Ur-Rehman
Journal:  Patient Prefer Adherence       Date:  2019-12-13       Impact factor: 2.711

8.  Coverage of different health insurance programs and medical costs associated with chronic hepatitis C infection in mainland China: a cross-sectional survey in 20 provinces.

Authors:  Hai-Yang Zhou; Shuang Liu; Su-Jun Zheng; Xiao-Xia Peng; Yu Chen; Carol Duan; Qing-Fen Zheng; Zhao Wang; Zhong-Ping Duan
Journal:  Hepatol Med Policy       Date:  2016-04-28

9.  Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis.

Authors:  T Joseph Mattingly; Julia F Slejko; Eberechukwu Onukwugha; Eleanor M Perfetto; Shyamasundaran Kottilil; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2020-02       Impact factor: 4.981

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.